Nuvectis Pharma
NVCT
41 hedge funds and large institutions have $7.63M invested in Nuvectis Pharma in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 16 closing their positions.
3% more funds holding
Funds holding: 40 → 41 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
2.23% less ownership
Funds ownership: 8.79% → 6.56% (-2.2%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
40% less capital invested
Capital invested by funds: $12.8M → $7.63M (-$5.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$543K |
| 2 |
Goldman Sachs
New York
|
+$418K |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$158K |
| 4 |
Jane Street
New York
|
+$116K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.97M |
| 2 |
State Street
Boston,
Massachusetts
|
-$775K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$553K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$324K |
| 5 |
Morgan Stanley
New York
|
-$211K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
51
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$4.64K | -566 | Closed |
|
|
TCOV
52
Trust Company of Vermont
Brattleboro,
Vermont
| – | -$4.1K | -500 | Closed |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -270 | Closed |
|
|
AB
54
Amalgamated Bank
New York
| – | -$2K | -231 | Closed |
|
|
GI
55
GAMMA Investing
Foster City,
California
| – | -$205 | -25 | Closed |
|
|
AWM
56
Avior Wealth Management
Omaha,
Nebraska
| – | -$8 | -1 | Closed |
|
57
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$109 | +16 | New |
|
NVCT Hedge Fund Activity: Q2 2024 in Review
41 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q2 2024, worth a combined $7.63M — down 40% from $12.8M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NVCT positions and 16 closed out — a net gain of 1 holder — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, adding an estimated $543K. The largest seller was BlackRock, cutting an estimated $1.97M.
- 41 institutional investors held Nuvectis Pharma (NVCT) as of Q2 2024, up from 40 in Q1 2024.
- Funds reported $7.63M of Nuvectis Pharma stock for Q2 2024, down 40% quarter-over-quarter.
- 17 funds opened new Nuvectis Pharma positions in Q2 2024 and 16 closed out, a net change of +1 holder.
- The largest Nuvectis Pharma buyer in Q2 2024 was Millennium Management, an estimated $543K added.
- The largest Nuvectis Pharma seller in Q2 2024 was BlackRock, an estimated $1.97M sold.
Based on aggregated 13F filings for Q2 2024.